Recombinant Human Anti-CTLA4 x Human Anti-PD1 Bispecific Antibody (Tandem scFv-Fc) (BSFVF-H315)

Recombinant Anti-CTLA4 x Anti-PD1 Bispecific Antibody (Tandem scFv-Fc) is designed to be expressed as a homodimer, which has 2+2 antigen-binding valency. This format consists of one Fc region and two tandem scFv fragments, in which the anti-CTLA4/PD1 tandem scFv is fused to the Fc domain. The engineered fragment format is used to extend the half-life. This BsAb can bind two factors simultaneously and enhance immune response. It is designed for the research of Tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CTLA4 & PD1

Type

Constant Domain-extended Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Tumors

Targets

Target 1

CTLA4

Gene ID

1493

UniProt ID

P16410

Alternative Names

CTLA4; cytotoxic T-lymphocyte-associated protein 4; CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3; cytotoxic T-lymphocyte protein 4; CD152 isoform; celiac disease 3; insulin-dependent diabetes mellitus 12; cytotoxic T-lymphocyte-associated serine esterase-4; cytotoxic T lymphocyte associated antigen 4 short spliced form; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4

Target 2

PD1

Gene ID

5133

UniProt ID

Q15116

Alternative Names

PDCD1; programmed cell death 1; PD1; PD-1; CD279; SLEB2; hPD-1; hPD-l; hSLE1; programmed cell death protein 1; protein PD-1; systemic lupus erythematosus susceptibility 2

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CTLA4 x Human Anti-PD1 Bispecific Antibody (Tandem scFv-Fc) (BSFVF-H315). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CTLA4 x Human Anti-PD1 Bispecific Antibody (Tandem scFv-Fc) (CAT#: BSFVF-H315)

Specifications

Targets

Customer Reviews and Q&As